We are live on ! Find out more
AIM

AIM ImmunoTech
AIM

14 hedge funds and large institutions have $1.38M invested in AIM ImmunoTech in 2017 Q1 according to their latest regulatory filings, with 4 funds opening new positions, 3 increasing their positions, 3 reducing their positions, and 1 closing their positions.

New
Increased
Maintained
Reduced
Closed

300% more first-time investments, than exits

New positions opened: 4 | Existing positions closed: 1

0% more funds holding

Funds holding: 14 → 14 (0)

0% more repeat investments, than reductions

Existing positions increased: 3 | Existing positions reduced: 3

46% less capital invested

Capital invested by funds: $2.57M → $1.38M (-$1.19M)

Holders
14
Holders Change
–
Holders Change %
0%
% of All Funds
0.35%
Holding in Top 10
–
Holding in Top 10 Change
–
Holding in Top 10 Change %
–
% of All Funds
–
New
4
Increased
3
Reduced
3
Closed
1
Calls
–
Puts
–
Net Calls
–
Net Calls Change
–

Top Buyers

Rank Fund Capital Flow
1
BlackRock
BlackRock
New York
+$286K
2
Creative Planning
Creative Planning
Kansas
+$23K
3
Vanguard Group
Vanguard Group
Pennsylvania
+$12.8K
4
Bank of New York Mellon
Bank of New York Mellon
New York
+$7.67K
5
GC
Guggenheim Capital
Illinois
+$7.67K

Top Sellers

Rank Fund Capital Flow
1
AFM
Anson Funds Management
Texas
-$739K
2
SM
Sabby Management
Florida
-$130K
3
Susquehanna International Group
Susquehanna International Group
Pennsylvania
-$10.2K
4
Renaissance Technologies
Renaissance Technologies
New York
-$5.11K
Name Holding Trade Value Shares
Change 		Change in
Stake
SM
1
Sabby Management
Florida
$638K -$130K -51 -16%
BlackRock
2
BlackRock
New York
$269K +$286K +112 New
Vanguard Group
3
Vanguard Group
Pennsylvania
$246K +$12.8K +5 +5%
Renaissance Technologies
4
Renaissance Technologies
New York
$73K -$5.11K -2 -6%
Geode Capital Management
5
Geode Capital Management
Massachusetts
$40K – – –
Susquehanna International Group
6
Susquehanna International Group
Pennsylvania
$22K -$10.2K -4 -31%
Creative Planning
7
Creative Planning
Kansas
$22K +$23K +9 New
Northern Trust
8
Northern Trust
Illinois
$17K +$7.67K +3 +75%
PAM
9
Panagora Asset Management
Massachusetts
$14K +$7.67K +3 +100%
OAM
10
Occidental Asset Management
California
$9K – – –
Bank of New York Mellon
11
Bank of New York Mellon
New York
$9K +$7.67K +3 New
GC
12
Guggenheim Capital
Illinois
$7K +$7.67K +3 New
UBS Group
13
UBS Group
Switzerland
$5K – – –
WPW
14
Waldron Private Wealth
Pennsylvania
$5K – – –
Morgan Stanley
15
Morgan Stanley
New York
$1K – – –
AFM
16
Anson Funds Management
Texas
– -$739K -244 Closed

AIM Hedge Fund Activity: Q1 2017 in Review

14 of the 4,017 institutional investors tracked by Wall St. Rank reported a position in AIM ImmunoTech (AIM) for Q1 2017, worth a combined $1.38M — down 46% from $2.57M a quarter earlier.

Buyers outnumbered sellers: 4 funds opened new AIM positions and 1 closed out — a net gain of 3 holders — while 3 added to existing stakes and 3 trimmed.

The largest buyer was BlackRock, opening a new position worth an estimated $286K. The largest seller was Anson Funds Management, exiting entirely with an estimated $739K sold.

  • 14 institutional investors held AIM ImmunoTech (AIM) as of Q1 2017, unchanged from Q4 2016.
  • Funds reported $1.38M of AIM ImmunoTech stock for Q1 2017, down 46% quarter-over-quarter.
  • 4 funds opened new AIM ImmunoTech positions in Q1 2017 and 1 closed out, a net change of +3 holders.
  • The largest AIM ImmunoTech buyer in Q1 2017 was BlackRock, an estimated $286K added.
  • The largest AIM ImmunoTech seller in Q1 2017 was Anson Funds Management, an estimated $739K sold.

Based on aggregated 13F filings for Q1 2017.